NIH wants Big Pharma’s help with coronavirus
The National Institutes of Health has picked Moderna Therapeutics as its partner in the quest to develop a vaccine for the novel coronavirus. The problem is that Moderna, despite employing more than 700 people, doesn’t have the wherewithal to make the millions of doses the world would need if the vaccine ends up working. That means NIH needs to recruit a pharma giant to help with manufacturing, and the process of doing so has been “very difficult and very frustrating,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
Speaking to STAT’s Helen Branswell, Fauci acknowledged major drug makers might have their reasons to be reticent. In the past, responding to outbreaks has been a money-losing endeavor, one that sometimes ends with reputational damage.
While NIH looks for a suitor, Johnson and Johnson said yesterday it would partner with another U.S. agency, BARDA, on its own product.
Read more.
Speaking to STAT’s Helen Branswell, Fauci acknowledged major drug makers might have their reasons to be reticent. In the past, responding to outbreaks has been a money-losing endeavor, one that sometimes ends with reputational damage.
While NIH looks for a suitor, Johnson and Johnson said yesterday it would partner with another U.S. agency, BARDA, on its own product.
Read more.
.png)
No hay comentarios:
Publicar un comentario